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Serum Leukotriene Metabolism and Type I Hypersensitivity 
Reactions in Different Animal 
The peptidoleukotrienes, leukotriene C4, leukotriene D4 
and leukotriene E4/ (LTC4, LTD4, and LTE4) which are products 
of the 5-lipoxygenase pathway of arachidonic acid 
metabolism, play important roles in mediating 
hypersensitivity reactions. LTC4 is the primary leukotriene 
released from stimulated cells. A transpeptidase activity 
converts LTC4 to LTD4, which is subsequently converted to 
LTE4 bya dipeptidase activity. LTC4 metabolism was studied 
in human, mouse, guineapig, rabbit, horse and cow sera. 
LTD4 is the most potent of the peptidoleukotrienes. The 
relative amounts of LTD4 present after specific periods of 
incubation was compared in the sera of different species, 
using tritium labelled LTC4 (3H-LTC4) After specific 
incubation time, the lipids were extracted from the serum, 
and the leukotrienes separated by Reverse Phase High 
Pressure Liquid Chromatography. The leukotrienes in the 
different fractions were quantitated based on the 
radioactivity in the corresponding fractions. The profile 
of metabolism was different for each species in that the 
rate of formation of LTD4 (transpeptidase activity) and the 
rate of LTD4 metabolism (dipeptidase activity) varied in the 
different species. On the basis of these two enzymatic 
activities, the different animal species tested could be 
divided into four categories; (1)those with high 
transpeptidase and dipeptidase activity, which would result 
in large amount of LTD4 accumulation initially, with a rapid 
decline, as in horse and cow:(2)those with low activity of 
transpeptidase and dipeptidase, resulting in accumulation of 
formed LTD4, as in guineapig;(3)those with high 
transpeptidase activity and a low dipeptidase activity which 
would result in accumulation of large amounts of LTD4, as in 
humans;(4)those with low transpeptidase and high dipeptidase 
activitywhich results in very low or no accumulation of LTD4 
as in mouse. The results show a relationship between the 
relative amounts of LTD4 observed and the manifestation of 
Type I hypersensitivity in the different species. 
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INTRODUCTION 
Arachidonic acid (a 20-C polyunsaturated fatty acid), 
is a 5,8,11/14-eicosatetraenoic acid. Arachidonic acid (AA) 
and its metabolites are known to play important roles in 
mediating hypersensitivity reactions like bronchial asthma, 
allergic rhinitis and psoriasis (24, 32) . 
Arachidonic acid is usually present in membrane 
phospholipids (phosphatidyl choline, phosphatidyl inositol, 
etc.) esterified primarily to the second carbon (C-2) 
position. Release of AA from the C-2 position is mediated 
by different types of stimuli, which can be physiological or 
pathological (64). Hormones like angiotensin, bradykinin, 
epinephrine, antigen-antibody complexes etc. are 
physiological stimuli, whereas ischaemia, mechanical damage, 
membrane-active venoms (like mellitin from bee venom), Ca2+ 
ionphores (A23187), phorbol esters etc. are pathological 
stimuli. The membrane AA is released by the effect of two 
phospholipase: phospholipase C, which is specific for 
phosphatidyl inositol, and phospholipase A2, which is 
specific for phosphatidyl choline (Fig. 1). In general, all 
stimuli lead to changes in cell membrane, which lead to 
transport of ions across the membrane, especially a flow of 
Ca2+ ions from the extracellular to the intracellular 
1 
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Fig. 1. Mechanisms involved in release of arachidonic acid. 
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compartment. The resulting increased intracellular Ca2+ 
concentration stimulate the cytoplasmic phospholipase C, 
which acts on phosphatidyl inositol to give 
inositoltriphosphate (IP3) and diacylglyceride (DAG). DAG 
is acted upon by other lipases to a monoacylglyceride and 
AA. IP3 induces further Ca2+ mobilization from the 
endoplasmic reticulum to the cytoplasm, and this further 
activates phospholipase C. The DAG which is not converted 
to monoglyceride, stimulates other enzymes. Protein kinase 
C (PKC) is a major enzyme activated by DAG. PKC 
phosphorylates a phospholipase A2 inhibitory protein. This 
causes activation of phospholipase A2, which cleaves AA from 
phosphatidyl choline (64). The released AA has a very short 
half life. It is either metabolized, by a cyclooxygenase or 
a lipoxygenase pathway, or is reincorporated into the 
membrane phospholipids. Very small amounts of AA are found 
in the free fatty acid pool. This low level is thought to 
be maintained by the action of an acyl-CoA transferase, 
which esterifies arachidonyl-CoA into phospholipids (25). 
The metabolism of AA by the lipoxygenase and the 
cyclooxygenase pathways are together known as the 
arachidonic acid cascade (Fig. 2). Metabolism by the 
cyclooxygenase pathway leads to the formation of 
prostaglandins (PGs) . The first PG to be formed is PG-G2. 
This is converted to PG-H2 from which other PGs and 
thromboxanes are formed. 
4 
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Fig. 2. The arachidonic acid cascade. 
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The lipoxygenase pathways involve metabolism by 5-, 15-
and 12-lipoxygenases. Lipoxins are produced by the 15-
lipoxygenase pathway, and hydroxy eicosatetraenoic acids 
(HETES) are produced by the 12-lipoxygenase pathway. 
The 5-lipoxygenase pathway converts AA to 5-
hydroperoxy,6,8,11,14 eicosatetraenoic acid (5-HPETE). 5-
HPETE can then undergo enzymatic conversion to 5-HETE or to 
5,15,diHETE. Leukotriene A4 (LTA4) is formed from 5-HPETE 
by an LTA4 synthase. LTA4 is very unstable. The action of 
an LTA4 hydrolase converts LTA4 to LTB4, which is relatively 
stable. LTB4 can also be formed from 5-HETE, in the 
presence of cytochrome P-450 (64). Conversion of LTB4 to 
its wOJ -metabolites by Polymorphonuclear cells (PMNs) has 
been reported. 20-carboxy LTB4 and 20-hydroxy LTB4 are the 
products of Co -oxidation. 
LTA4 undergoes enzymatic conversion to LTC4 by the 
action of a glutathione-S-transferase, which is specific for 
LTA4. Addition of a glutathione residue to the C-6 position 
by a sulfo-ether linkage, leads to the formation of LTC4, 
which is the first peptidoleukotriene to be formed. LTC4, 
along with its metabolites, LTD4 and LTE4 were formerly 
known as the Slow Reacting Substances of Anaphylaxis 
(SRS-A), Although SRS-A has been identified as early as 
1930 it was only in 1980 that it was found to be a mixture 
of peptidoleukotriens (7) . The main component of the SRS-A 
is LTD4 (48) . The name leukotriene refers to the 
6 
observation that they were seen to be released by 
leukocytes, and had three conjugated double bonds. 
LTC4 is the form in which the peptidoleukotrienes are 
released into the extracellular medium. LTC4 is converted 
to LTD4 by transpeptidase reaction (64) that removes the 
glutamate from the glutathione residue. LTD4 is further 
converted to LTE4 by a dipeptidase activity (64), which 
cleaves the glycine from LTD4. 
Several cell types are involved in the release of 
leukotrienes. LTB4 is released primarily from the PMNs 
(57,65). It is also released from bronchi and lung 
parenchyma (68). LTC4, on the other hand, is released 
predominantly from the eosinophils (57,65), mast cells, 
alveolar macrophages (24),and in lung, parenchymal 
tissue (68) . 
The metabolism of the peptidoleukotrienes has been 
studied in detail, both in vivo, and in vitro. In-vitro 
studies, showed conversion of LTC4 to LTD4 in Rat Basophil 
Leukemia (RBL-1) cells (42). The conversion of LTD4 to LTE4 
was also first detected in RBL-1 cells (43). In fact, the 
SRS-A was first shown to be a metabolite of AA in RBL-1 
cells (27). The metabolism of leukotrienes has also been 
studied in human plasma (1,31), and in the supernatant of 
PMNs (51). The transpeptidase activity responsible for the 
formation of LTD4 is released by PMNs, as seen by the 
formation of LTD4 from LTC4 in the supernatant of a 
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Fig. 3. Metabolism of the peptidoleukotrienes. 
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suspension of PMNs (51). The transpeptidase activity and 
dipeptidase activity were seen to be released from PMNs 
following immunological as well as nonimmunological stimuli 
(54). The transpeptidase activity was seen to be localized 
in the microsomal fraction of PMNs, by subcellular 
fractionation (51). This activity has also been detected in 
plasma (1), in the supernatant of alveolar macrophages, 
(15), and in the parenchyma of human and guinea pig lung 
tissue (53,54) . The transpeptidase activity that converts 
LTC4 to LTD4 is thought to be due to a Y*-glutamyl 
transferase, as glutamate was seen to be a substrate for 
this enzyme (23) and since inhibitors of Y-glutamyl 
transferase (L-serine borate, avicin) (43) inhibited the 
formation of LTD4. 
Other than conversion to LTD4, LTC4 can also undergo 
oxidative metabolism to biologically inactive products (33). 
This reaction was seen to take place during the respiratory 
burst in PMNs. Sulfoxides of LTC4, like LTC4 chlorsulfonium 
ion, are metabolites of this oxidative metabolism. 
LTD4 is converted to LTE4 by a dipeptidase activity 
(64), which was associated with specific granules of PMNs 
(34 ), and plasma membrane of RBL-1 cells (51). This 
activity is present in alveolar macrophages, and in lung 
parenchyma, as shown by the presence of LTE4 in these 
tissues following antigen challenge (17). L-cysteine is a 
dipeptidase inhibitor (43). The dipeptidase activity also 
9 
requires the presence of divalent cations. Substances like 
L-cysteine and dithiothreotol, which bind divalent cations, 
decreased the dipeptidase activity, which was subsequently 
restored by the addition of Co2+, Zn2+, or Mn2+ into the 
system (52) . 
LTE4 is relatively stable. It can undergo further 
conversion to N-acetyl LTE4 in the presence of acetyl Co-A. 
This has been shown by the use of 14C-Acetyl CO-A (23) . LTE4 
and N-acetyl LTE4 are the main excretory metabolites of 
peptidoleukotriene metabolism in man and other mammalian 
species (6,60) . N-acetyl LTE4 can also be converted to 20-
carboxy N-acetyl LTE4 and 20-hydroxy N-acetyl LTE4 (23) . 
Addition of a glutamate residue to LTE4 by a Y-glutamyl 
transferase leads to the formation of LTF4, which is a V-
glutamyl-cysteinyl leukotriene(23). 
Other than arachidonic acid, trienoic and pentaenoic 
acids were also seen to be metabolized to 
peptidoleukotrienes LTC3 and LTCS, as seen by the presence 
of LTE3 and LTES in RBL-1 cells. These leukotrienes, with 3 
or 5 double bonds, were seen to cross react with anti-LTC4 
antibodies. The biological activity and enzyme 
specificities of these leukotrienes were seen to be similar 
to that of the leukotrienes with four double bonds (43). 
The biological activities of the different leukotrienes 
have been described (55) . LTB4 is mainly chemotactic in 
activity. It facilitates migration of all leukocytes, but 
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the PMNs are mainly affected. LTB4 also increases 
microvascular permeability. The peptidoleukotrienes, also 
referred to as the cysteinyl leukotrienes, have a smooth 
muscle constrictor effect, and thus induce bronchospasm. 
LTC4, LTD4 and LTE4 are reported to be 100 to 1, 000 times as 
potent as histamine, on a molar basis (48,55) . Other than 
their direct constrictor effect on airway smooth muscle, 
they can also potentiate the action of other inflammatory 
mediators. LTC4 and LTD4 increase microvascular 
permeability and mucous secretion in bronchioles. These 
activities suggest that the cysteinyl leukotrienes are the 
major mediators of type I hypersensitivity reactions like 
bronchial asthma, allergic rhinitis and anaphylactic shock. 
Four types of hypersensitivity reactions are recognized: 
Type I, Type II, Type III and Type IV (64). These are 
inflammatory reactions, mediated by the release of 
pharmacologically active substances like histamine and 
leukotrienes, from specific cell types, following antigen-
antibody reactions. The Type I reactions are more acute, 
and cause more discomfort. This type of reaction is 
referred to as immediate hypersensitivity reaction, allergy 
or anaphylaxis. Antigen-antibody reactions cause release of 
AA and its metabolites directly from cell membranes of mast 
cells. AA metabolites, like leukotrienes, which are 
mediators of hypersensitivity reactions are also released 
directly by eosinophils, which are attracted to the site of 
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the reaction by chemotactic substances released by mast 
cells. These substances are called eosinophil chemotactic 
substances of anaphylaxis (ECF-A). The symptoms of Type I 
hypersensitivity can be attributed to the sum total of all 
the above factors. Bronchial asthma, which is a Type I 
hypersensitivity reaction , is characterized by severe 
prolonged bronchoconstriction and airway obstruction, both 
of which are due to the release of these mediators. In 
fact, several workers have reported the presence of elevated 
plasma levels of cysteinyl leukotrienes during the 
asthmatic attack (40,56,68). Eosinophils from asthmatic 
individuals have been reported to produce larger amounts of 
LTC4 than those from normal individuals (59). The Type II 
hypersensitivity reaction results in cell destruction due to 
antigen-antibody reactions. Blood group incompatibilities 
fall into this group. The Arthus reaction, acute and 
chronic serum sickness which come under the Type III 
hypersensitivity reaction are produced by localized tissue 
damage due to deposition of immune complexes. Type IV 
hypersensitivity reactions are cell mediated reactions, in 
response to localized injection of antigen. It is mediated 
through lymphocytes and is called delayed hypersensitivity 
reaction (DHR). 
The metabolism of LTB4 in human blood has been 
studied (71). It was seen that LTB4 slowly undergoes co-
oxidation, to 20-hydroxy and 20-carboxy LTB4. There was no 
difference in the rate of metabolism between normal and 
asthmatic individuals, suggesting that this pathway may not 
influence the outcome in a hypersensitivity state. 
The cysteinyl or peptidoleukotrienes have been 
implicated in a wide variety of hypersensitivity disorders 
eg., bronchial asthma (56,59), psoriasis (10) and allergic 
rhinitis (67). In an allergic condition, the eosinophils, 
which release the peptidoleukotrienes, are thought to be 
attracted to the tissue by the LTB4 released by the PMNs 
(57) . LTC4 is the form in which the SRS-A is released from 
stimulated cells. Therefore, the high levels of LTD4 
detected in the plasma of individuals during the asthmatic 
attack (40), and the LTD4 and LTE4 seen following antigen 
challenge in human (17) and guinea pig (53) lung, must be 
due to the presence of metabolizing enzymes released into 
the medium. The release of these enzymes following antigen 
challenge have been shown by several workers (15). An 
elevated amount of leukotriene release has been reported 
from the lung (14), and stimulated blood cells (eosinophils) 
of individuals with allergic asthma and chronic bronchial 
asthma (59). This observation suggests that an increased 
release of leukotrienes might be the factor that predisposes 
these individuals to the development of hypersensitivty 
reactions. 
A comparison of the urinary LTE4 levels in normal and 
atopic individuals after antigen challenge, and in asthmatic 
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individuals during the asthmatic attack, showed that 
although the LTE4 levels were elevated in atopic individuals 
following antigen challenge, they were not elevated in 
individuals during the acute asthmatic attack, or in 
individuals having a severe episode of allergic rhinitis 
(60). These results suggest that if an increased release 
of LTs does occur during an acute asthmatic attack, there 
might be an alteration in the further metabolism of these 
leukotrienes to a biologically less active and excretable 
form, as increased levels were not detected in the urine 
during the acute attack. 
Bronchial asthma is an anaphylactic reaction. 
Therefore , anaphylaxis induced in animal models should 
serve as an excellent model to study the role of leukotriene 
metabolism in bronchial asthma, and in hypersensitivity 
reactions as a whole. Although the phenomenon of 
hypersensitivity was observed in 1839 by Magendie, in 
rabbits, it was Richet, in 1902, who first recognized the 
reaction in dogs and named it "anaphylaxis" meaning "without 
protection" (50). Theobald Smith, in 1905, noted the ease 
with which guinea pigs developed anaphylaxis as compared to 
other animals (50). Thus guinea pigs became the 
experimental animal of choice to elicit the anaphylactic 
reaction in future experiments. The symptoms of anaphylaxis 
in guinea pigs were seen to resemble those in humans. The 
bronchoconstriction observed, was similar to that in 
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bronchial asthma (Burson, 1911, as quoted by Alexander, 
1926) (3). Later, Chase reported that it was possible to 
elicit the cutaneous anaphylactic reaction in guinea pigs, 
just as in humans. Experiments conducted by Rabat in 1942 
(28), indicated that very small amounts of antigen was 
sufficient to induce anaphylaxis in guinea pigs. Isolated 
guinea pig smooth muscle was also found to have the same 
amount of responsiveness to antigen as the intact animal. 
The amount of antigen required to produce fatal anaphylaxis 
was also found to be very small (29). Guinea pig smooth 
muscle was used as early as 1926 to elicit the Schultz-Dale 
reaction, in order to elicit the sensitivity of smooth 
muscle to antigen. This experiment is used widely, to study 
the effect of several mediators of anaphylaxis, because the 
symptoms of anaphylaxis are due to smooth muscle 
constriction. In many recent reports, the guinea pig has 
been used to elicit the anaphylactic reaction, in order to 
study the role of leukotrienes in anaphylaxis (30,53,62,63). 
Release of leukotrienes from trachea (53) and lung (62) of 
guinea pig following antigen challenge has been reported. 
These findings are also similar to reports of identical 
experiments conducted on human lung tissue (54). 
The mechanism of anaphylaxis was studied in mice by 
Weisser and coworkers in 1941 (69). A series of experiments 
were conducted to determine the susceptibility of mice to 
develop anaphylaxis after active and passive sensitization. 
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The mice responded with little or no signs of anaphylaxis, 
and none showed fatal anaphylaxis. Hours after unilateral 
adrenalectomy, two mice had fatal shock, while the majority 
of animals died of shock after bilateral adrenalectomy. 
Sobey and Adams, in 1959, used a score, called anaphylactic 
score, to study the anaphylactic reaction in a batch of 
mother and daughter mice (58). This was based on symptoms 
like itching and decreased activity. A wide variation was 
found in the anaphylactic score in different mice. Based on 
these observations, they concluded that the anaphylactic 
potential of a mouse was determined by that of its mother 
and that this potential was under genetic control. The 
development of passive cutaneous anaphylaxis (PCA) was also 
found to be much slower in mice than in guinea pigs, and 
required a much larger dose of antigen (45). These findings 
were later supported by Levy in 1964 (35), who developed a 
technique to elicit PCA and reverse passive Arthus reactions 
simultaneously. A difference was noticed between three 
animal species. The mouse was found to be least sensitive 
to these cutaneous reactions, showing only a mild reaction 
to undiluted antigen. The rat was about 10 times more 
sensitive than the mouse, responding to 1/10 dilution, 
whereas the guinea pig was 1,000 times more sensitive than 
the mouse, since anaphylaxis was induced by a 1/1,000 
dilution of the antigen. The difficulty in eliciting 
anaphylaxis and fatal shock in rats has also been described 
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(49). Bilateral adrenalectomy was necessary to induce signs 
of fatal shock. The difficulty in inducing the Arthus 
phenomenon in rats, as compared to guinea pigs and rabbits 
has also been described (41). 
The development of anaphylaxis in rabbits has been 
described as early as 1911 (Auer, as quoted by Coca in 1919) 
(16). The anaphylactic reaction in rabbits does not 
resemble that in humans. Although during anaphylaxis 
symptoms of respiratory distress were present, 
bronchoconstriction was not seen in rabbits. The cause of 
death in fatal shock was cardiac failure, due to increased 
pulmonary arterial pressure, as opposed to bronchiolar spasm 
in guinea pigs (50). This is explained by the fact that in 
rabbit, the pulmonary artery has a well developed smooth 
muscle layer, while the bronchiolar musculature does not. 
Manwaring used rabbit smooth muscle to study the response to 
antigens (36). It was found that although the animal 
developed fatal shock, smooth muscle contraction, as 
recorded by rise in intra cystic pressure, was very rare in 
rabbits, when compared to guinea pigs. Recent experiments 
have shown that LTC4 and LTD4 were seen to produce strong 
contraction in guinea pig lung parenchyma, while in rat and 
rabbit lung parenchyma, the dose required to produce a 
similar contraction was 3-4 fold higher (47). 
Horse and cattle anaphylaxis are noted to have some 
similarity to human reactions (50). Dyspnoea, increased 
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peristalsis, and sweating are the main symptoms. In horses, 
the anaphylactic response is characterized by acute 
hypotension, followed by increased pulmonary arterial 
pressure and respiratory distress within 8-12 minutes. In 
cattle, similar symptoms are described, with severe 
reactions taking 15-20 minutes to manifest themselves. In 
both species death is reported to occur in 2-5 minutes (8). 
In the calf, abdominal distension is a marked feature. This 
was explained by the presence of a strong smooth muscle 
layer in the stomach compartments (50). 
It is clear from the above data that a difference 
exists in the susceptibility of different species to develop 
anaphylaxis. The role of the peptidoleukotrienes in 
anaphylaxis has also been established. Studies have been 
done on in-vivo LTC metabolism in different species and 
differences in the metabolite that accumulates after 
specific periods of time have been reported (4, 23,44). In 
vitro studies have been done to study the products of 
metabolism and the comparative uptake of LTC by isolated 
organs and cells (23). The results of these studies showed 
a differential uptake by different organs. Metabolism of 
LTC4 has been studied in human plasma. Although human 
plasma was seen to convert LTC4 to LTD4 and LTE4 (1,31), LTD 
was not seen in the mouse or guinea pig tissues in in-vivo 
studies using LTC (4,22) . In vivo studies on the metabolism 
of leukotrienes in different species has also shown that the 
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form in which the leukotrienes are excreted differed with 
the species. In humans, LTE4 was the main excretory 
metabolite of LTC4 metabolism (60,66), while in monkeys, N-
acetyl LTE4 was the form in which the peptidoleukotrienes 
were excreted (6) . In rats, N-acetyl LTE4 was the main 
metabolite (44). Considering these observations, it seemed 
likely that the profile of LTC4 metabolism in the serum of 
these animal species would differ. This assumption was 
supported by observations made during our preliminary 
experiments using human and mouse serum (11). The profile 
of LTC4 metabolism in mouse serum was seen to be very 
different from that in human serum, in that, after a 
specific incubation period, no LTD4 was detected in mouse 
serum; most of the leukotriene detected was in the form of 
LTC4, with small amounts present in the LTE4 fraction. 
Under the same conditions, human serum showed presence of 
significant amounts of LTD4 and LTE4, with very little LTC4. 
Since LTD4 is known to be the most potent biologically among 
the peptidoleukotrienes, this observation correlated with 
the present knowledge concerning the susceptibility to the 
development of anaphylaxis in mice and humans. 
This study is intended to compare the profiles in LTC4 
and LTD4 metabolism in human, mouse, rabbit, guinea pig, 
horse, cow and fetal calf sera. 
THESIS OBJECTIVES: The role of peptidoleukotrienes in 
anaphylaxis has been established. A species specific 
susceptibility to develop anaphylaxis has also been 
described. The main objectives of this study are to 
determine 1) if a species specific difference exists in the 
metabolic profile of LTC4, which is the form in which the 
peptidoleukotrienes are released, and 2) if the anaphylactic 
susceptibility of an animal correlates with the profile of 
its LTC4 metabolism. 
MATERIALS AND METHODS 
Collection of Animal Blood and Sera 
Human blood collected from normal human volunteers, 
with no history of asthma or other allergic manifestations, 
was drawn from the cubital vein into heparin free 
vacutainers. The source of mouse blood was Balb-C mice in 
all experiments except the last one, in which the strain of 
mice used was Swiss Webster (SW) mice. The blood collected 
from several mice by way of the brachial artery, or the 
guillotine method was pooled. For rabbit blood, the New 
Zealand White strain of rabbit was used. Blood was 
collected by puncturing the marginal vein of the ear lobe 
with a 22 gauge needle. Guinea pig blood was collected from 
Duncan Hartley guinea pigs by cardiac puncture. The horse, 
as well as the cow were bled from the jugular vein into 
heparin free vacutainers. Fetal Bovine Serum (FBS) was 
purchased from Sigma Chemicals (Sigma Culture Reagents). 
In all cases except with mice and rabbit, the blood was 
drawn into vacutainers. Pooled mouse blood was collected 
in centrifuge tubes, and rabbit blood from the marginal vein 
of the ear lobe was allowed to flow into the centrifuge 
tubes. 
Clotting of Blood: 
The blood was incubated at room temperature until 
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clotting occurred, (usually 1 hour to 90 minutes), and 
centrifuged using a clinical centrifuge (International 
Equipment) for 20 minutes at room temperature. The serum 
that was not used was transferred to vials and stored at 
-70°C. 
Since changes in activity of enzymes were noticed using 
stored serum, a standard method was chosen for clotting 
procedures in order to ensure that all samples were being 
treated under the same conditions. The blood collected into 
heparin free vacutainers or conical centrifuge tubes was 
placed on ice until they could be placed in a 30°C water 
bath. Clotting was allowed to take place at 30°C for one 
hour. The clotted blood was centrifuged at 2,000 rpm for 
ten minutes at 4°C. The serum collected was maintained at 
4°C until use. The serum that was not used immediately was 
stored in vials of 1 ml each at -70°C. The glassware, 
syringes, and all other instruments used were sterilized 
prior to bleeding. 
Enzyme Assays: 
Substrates: Synthetic unlabeled leukotrienes LTC4, 
LTD4, and LTE4 were purchased from Cayman Chemicals, Ann 
Arbor, Michigan. The preparations contained 0.1 mg/ml of 
leukotrienes, dissolved in 0.25 ml of 1:1 ethanol/PBS. 
Tritium labeled leukotrienes were purchased from DuPont-NEN 
products. The specific radioactivity of the leukotrienes 
was 39.3 Ci/m mol, (2.2 X 106 dpm//1!) in 0.5 ml of 50% 
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ethanol, 0.01 M 2K2P04, at a pH of 6.8. 
Unlabeled leukotriene (160 p mols) mixed with 22,000 
dpm of tritium labeled leukotrienes was used as a substrate. 
Hartmann's Solution (Lactated Ringer Solution): 
Potassium chloride - 0.03 gms 
Sodium chloride - 0.6 gms 
Calcium chloride - 0.02 gms 
Sodium Lactate - 0.31 gms 
Made up to 100 ml using dd H20. 
Assay Mixture: 
The assay mixture consisted of 100 ft-l of undiluted 
serum (unless otherwise mentioned). A stock solution of 
the leukotriene mix was made up in Hartmann's solution 
containing 1% Triton X-100 so that each sample received 160 
pmols (22,000 dpm) of leukotriene and 25 /*1 of 1% Triton X-
100. This gave an effective dilution of 0.1% Triton X-100 
in the assay mixture), the volume of which was made up to 
250 ul with Hartmann's solution. Incubation was carried out 
at 37°C, for specific time periods. The reaction was stopped 
by the addition of two volumes of methanol at -20°C, 
containing butylated hydroxy toluene (BHT) as an 
antioxidant. After the addition of methanol, the samples 
were mixed well, and kept at -70°C for at least one hour 
prior to centrifugation, in order to precipitate proteins. 
The mixture was then centrifuged at 2,000 rpm for ten 
minutes at 4°C. The supernatant was transferred to conical 
centrifuge tubes, evaporated to dryness under vacuum at 
23 
40°C. Samples were stored at -70°C until HPLC analysis. 
The glassware used for the assays were siliconized using 
Sigmacote (Sigma Chemicals), in order to prevent adherence 
of LTs to the surfaces, and hence loss of the leukotrienes 
during extraction. 
RBL-1 Cells: 
Rat Basophilic leukaemia cells were purchased from 
American Tissue Culture Collection. The cells were 
maintained in Iscove's modified Dulbecco's medium containing 
L-glutamine, in the presence of 10% fetal calf serum. 
Stimulation of RBL-1 Cells: 
RBL-1 cells were washed twice with 1 ml of serum free 
media. The cells were resuspended in Phosphate Buffered 
Saline (PBS, Sigma Diagnostics) at a concentration of 
approximately 106/ml. The cells were stimulated using 
lipopolysaccharide (LPS) purchased from Ribi Immunochem 
10 ngms/ml, and calcium ionophore (A-23187, Sigma Chemicals) 
10 ngms/ml, for 30 minutes at 37°C in the presence of 5 mM 
calcium chloride (2) . After stimulation, leukotrienes were 
added, and the samples incubated for 30 minutes at 37°C 
before lipids were extracted. 
Lipid Extraction: 
Modified Bligh and Dyer procedure: This procedure was 
used in preliminary experiments using RBL-1 cells. After 
the specific incubation time, the cells were pelleted by 
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centrifugation in a clinical centrifuge. To the 
supernatant, two volumes of methanol were added, mixed 
well, and the proteins allowed to precipitate at -70°C. The 
protein precipitate was pelleted by centrifugation at 2,000 
rpm at 4°C, and to the supernatant, were added two volumes 
of chloroform, mixed well for one minute, centrifuged, and 
the chloroform fraction was separated by centrifugation in a 
clinical centrifuge. The chloroform fraction was collected 
in a conical centrifuge tube, evaporated to dryness under 
vacuum, and stored at -7 0°C until analyzed by reverse phase-
high pressure liquid chromatography (RP-HPLC). 
Sep-Pak procedure: After protein precipitation using two 
volumes of methanol, the supernatant was made up to contain 
20% methanol, using sodium phosphate buffer (0.1 M, pH 7.4). 
The sample was run through a C-18 cartridge (Bakerbond spe, 
J.T. Baker Inc.), pre-washed with 20 ml methanol and 20 ml 
water. The cartridge was then washed with 5 ml of 20% 
methanol in sodium phosphate buffer, followed by 5 ml of 
water. The leukotrienes in the cartridge were then eluted 
with 3 ml of 80% methanol in distilled water. This eluent 
was dried down, and analyzed by RP-HPLC. 
Direct evaporation technique: The Sep-Pak procedure 
resulted in low recovery of leukotrienes in the different 
fractions. So we developed a method, in which direct 
evaporation of the supernatant, after protein precipitation, 
was done. The evaporated sample was stored at -7 0°C, until 
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it was resuspended in solvent and analyzed by RP-HPLC. This 
procedure involved minimal loss of radioactivity in 
different fractions, and less loss by adherence to 
glassware. The presence of other substances with UV 
absorbance at 280 nm did not interfere with the analysis, 
since calculation were based only on radioactivity in 
different fractions. 
Reverse Phase High Pressure Liquid Chromatography (RP-HPLC) 
Analysis 
Solvent: The solvent system used was: acetonitrile: 
methanol: water: acetic acid (1280 / 800 / 1916 / 4, 
V/V/V/V). The pH was adjusted to 5.5 using ammonium 
hydroxide (5). The samples that had been evaporated to 
dryness were resuspended in 250 pi of solvent and injected 
into a Nucleosil 5-C18 (25 x 4.6) column (Phenomenex), 
maintaining a flow rate of 1.0 ml/min. A pressure of 60 psi 
was applied. The sample was eluted from the column, for a 
total time of 25 minutes. The column was then rinsed with 
100% methanol for 15 minutes. The solvent was then allowed 
to run through the column for 15 minutes to equilibrate the 
column before the next sample was injected. The 
peptidoleukotrienes have a max at 279 nm (38). 
The elution times of the different leukotrienes were 
marked (according to UV absorption peaks at 280 nm) using 
standard LTC4, LTD4, LTE4, LTF4 and N-acetyl LTE4. In initial 
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experiments, to quantify the relative amounts of 
leukotrienes present after each assay, the UV absorption 
peaks of the different leukotrienes at the characteristic 
elution times were matched with the radioactivity in the 
corresponding fractions. The fractions were collected using 
a Gibson model 203 micro fraction collector. The 
radioactivity in the fractions were then determined in a 
Beckman 7500 scintillation counter. The different 
leukotrienes were quantitated based on the percentage of 
total recovered radioactivity in each peak. In later 
experiments, a Flo-one Beta In-line radioactive flow 
detector (Radiomatic) was used in which the UV absorption, 
as well as the radioactivity of the eluted leukotrienes were 
simultaneously displayed. 
RESULTS: 
Evaluation of analytical procedures 
In the initial experiments with RBL-1 cells, a modified 
Bligh and Dyer technique of lipid extraction was compared to 
a technique using C-18 cartridges (Sep-Pak) (26) and one 
involving a direct evaporation of the methanol fraction 
after protein precipitation. The recovery of the 
leukotrienes by the Bligh and Dyer technique was 58.13% 
(S.D. 10.43,n=10), while the recovery using C-18 cartridges 
was 71.48% (S.D. 12.6,n=10), and that by the direct 
evaporation technique was 89.52% (S.D. 8.61,n=20). The 
elution profile for a mixture of the different leukotrienes 
is by RP-HPLC using the solvent system previously described, 
is shown in Fig. 4. 
Leukotriene Metabolism in RBL-1 Cells 
Initial experiments to study conversion of 3H-LTC4, 
standardization of lipid extraction and enzyme assay 
procedures were done using RBL-1 cells. RBL-1 cells, 
stimulated by bacterial lipopolysaccharide, in the presence 
of Ca2+ and A-23187 (calcium ionophore), were seen to 
produce both 3H-LTD4 and 3H-LTE„ from 3H-LTC4 (Fig. 5) . 
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Fig. 4. Relative elution times of standard leukotrienes -
LTC4, LTD4/ LTE4/ LTF4, and N-acetyl LTE4 .by RP-HPLC 
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Fig. 5. Metabolism of 3H-LTC4 in the supernatant of RBL- 1 
cells. RBL-1 cells were resuspended to a 
concentration of approximately 10 cells/ml and 
stimulated with LPS and A 23187 (calcium 
ionophore) in the presence of calcium. 1ml of the 
supernatant was assayed for transpeptidase 
activity and leukotrienes separated by RP-HPLC. 
Radioactivity was calculated at elution times 
corresponding to LTC4/ LTD4 and LTE4. Data is 
expressed as percent radioactivity at different 
elution times. 
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Leukoreiene Metabolism in Human Serum 
After procedures were standardized using RBL-1 cells, 
human serum from a normal volunteer was used. Table I shows 
the mean value and standard deviation of values obtained for 
the percent conversion of LTC4 after 30 min. incubation and 
for LTD4 after 15 min. incubation in six different serum 
samples. Conversion of 3H-LTC4 or 3H-LTD4 was not seen in 
serum at 4°C, Hartmann's solution at 37°C, or following 
denaturation of proteins(Fig.6,7). 3H-LTC4 was converted to 
3H-LTD4, which was then converted to 3H-LTE4 as seen by the 
relative amounts of the different leukotrienes present after 
15 and 30 minutes incubation (Fig.8). The experiment was 
repeated using serum from clotted blood, and plasma from 
heparinized blood. Heparinized blood showed a decrease in 
the formation of LTE4, compared to serum (Fig. 9). 
Thereafter, all experiments were conducted using serum. 
The effect of storage of serum on the conversion of 
LTC4 and LTD4 was studied using serum stored at 4°C, -20°C 
and -70°C. Prolonged storage resulted in significant loss 
of the LTD4 conversion at 4°C, but not at -70°C (Fig. 10) . 
The experiments that followed were all done using fresh 
serum, or serum that had been stored at -7 0°C immediately 
after collection of blood. 
The percent conversion of 3H-LTC4 to 3H-LTD4 and 
3H-LTE4 was seen to have a linear relationship with the 
volume of serum used (Fig. 11) . The conversion of 3H-LTC4 
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LTC4 LTD4 
Sample no. 
1 14 . 82 8 .71 
2 12 .50 12 .71 
3 16. 64 8 .31 
4 14.31 9.74 
5 15. 83 10 .56 
6 13.51 12.34 
Mean 14 . 60 10.39 
S. D. + 1.51 + 1 .83 
Table I.Mean and S.D. values for percent conversion of 3H-
LTC4 conversion (following 30 minutes incubation) 
and 3H-LTD4 (following 15 minutes incubation) in 
six serum samples. 
Fig. 6. Chromatogram showing LTC4 profile after 90 minutes 
incubation in (A) serum at 4°C (B) Hartmann's 
solution at 37°C and (C) protein denatured serum. 
Fig. 7. Chromatogram showing LTD4 profile after 45 minutes 
incubation in (A) serum at 4° C (B) Hartmann's 
solution at 37°C and (C) protein denatured serum. 
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Fig. 8. 3H-LTC4 metabolism in human serum. 1 ml of fresh 
human serum was incubated with 3H-LTC4 for 15 and 
30 minutes. The reaction was stopped using 2 
volumes of methanol. Leukotrienes were extracted 
using C-18 cartridges. The recovered leukotrienes 
were separated by RP-HPLC. Data shows percent 
radioactivity at different elution times 
corresponding to the different leukotrienes. 
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Fig. 9. Comparison of3H-LTC4 metabolized in clotted and 
heparinized blood, placed at 4 C for approximately 
24 hours. Assay procedure was as described in 
Figure 6. Figure shows relative amounts of LTC4/ 
LTD4 and LTE4 present in clotted and heparinized 
blood, as percent of total radioactivity after 60 
minutes incubation. 
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Fig. 10.Comaparison of 3H-LTC4 metabolism in fresh serum 
stored at 4°C for 4 days, -20°C for 7 days and 
-70 C for 7 days after 60 minutes incubation. 
Procedure was same as described in Figure 8. Data 
expressed as percent of total radioactivity at 
different elution times corresponding to the 
different leukotrienes. 
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Fig. 11. Relationship between enzyme concentration and 3H-
LTC4 metabolism in human serum. Varying amounts of 
human serum made up to 1ml using phosphate buffered 
saline, were assayed for transpeptidase activity 
using procedure described in Fig.8. Data shows 
percent of LTC4 metabolized (left y-axis) and 
picomoles of LTC4 converted (right y-axis). 
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Fig. 12.Relationship between incubation time and3H-LTC4 
metabolism in human serum. 0.5 ml serum was made 
up to 1 ml using PBS. Assay procedure as described 
in Fig 8. Data is expressed as percent LTC4 
converted (left y-axis) and picomoles LTC4 
converted (right y-axis). 
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Fig. 13.Relationship between substrated concentration and 
3H-LTC4 metabolism. Varying amounts of 3H-LTC4 of 
known specific radioactivity were used as 
substrate. Assay procedure was as described in 
Fig 8. Data expressed as picomoles of LTC4 
converted/ml/min. Incubation period was 15 
minutes. 
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(to 3H-LTD4 and 3H-LTE4) showed a linear relation to time 
(Fig. 12) . The conversion of LTC4 also showed a linear 
increase with respect to substrate concentration (Fig. 13). 
Leukotriene metabolism in mouse serum 
Using 3H-LTC4 as a substrate, the profile of LTC4 
metabolism was compared in mouse and human serum. The 
results, as shown in Fig. 14, show a great difference. 
After a 30 min incubation, with 0.5 ml of serum, 50% of the 
radioactivity was in the LTD4 and LTE4 fractions in human 
serum, 47% being present as LTD4. Whereas in mouse serum, 
all the radioactivity in the 15% of converted 3H-LTC4 was 
present in the region corresponding to the elution time of 
LTE4. A time course study using 3H-LTC4 showed a much higher 
activity in human serum than in mouse serum (Fig. 15). As 
this observation suggested a difference in the rate of LTD4 
metabolism, metabolism of 3H-LTD4 was compared in human and 
mouse sera (Fig. 16). The mouse serum was seen to have a 
much higher activity, 85% of the 3H-LTD4 being converted in 
the first 10 minutes of incubation time, while in human 
serum, only 17% was converted under identical conditions. 
The metabolism of 3H-LTD4 in both human and mouse sera was 
linear with relation to time and substrate concentration 
(Figs. 16 and 17). A difference was seen in the rate of 
conversion with relation to the concentration of enzyme 
(volume of serum) used, as shown in Fig. 18. Serial 
dilution of sera were used in this experiment, because the 
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rate of conversion of 3H-LTD'4 was seen to be much faster than 
that of 3H-LTC4. The rate of conversion of 3H-LTD4 did not 
decrease with increasing dilutions in human serum. This 
suggested the presence of some factor in the serum that 
inhibited the enzyme activity in the undiluted form, or in 
lower dilutions. Heating the sera to 65°C in a water bath 
for 30 min decreased the activity in both human and mouse 
serum. The activity in the heated sera of both species was 
the same (21%) as shown in Fig. 19. The effect of heat 
inactivated human and mouse serum on unheated human and 
mouse serum was studied (Fig. 20,21). The results show that 
while heat inactivated human serum was able to decrease LTD4 
conversion in normal human and mouse serum, heat inactivated 
mouse serum did not show the same effect. 
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Fig. 14.Comparison of profiles of3H-LTC4 metabolism in 
human and mouse serum after 30 minutes incubation. 
Procedure as described in Fig 8. Data expressed as 
percent radioactivity at different elution times. 
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Fig 15. Effect of incubation time on3H-LTC4 conversion in 
mouse and human serum. 100 ul serum, brought to a 
total volume of 250 ul with Hartmann's solution and 
at 0.1% Triton X-100, was incubated in the presence 
of 160 picomoles3H-LTC4 (22,000 dpms) at 37°C. 
Data expressed as percent of LTC4 converted (left y 
axis) and picomoles LTC4 converted (right y axis). 
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Fig. 16.Comparison of dipeptidase activity in human and 
mouse serum. Procedure as described in Fig 15, 
except3H-LTD4 was used as substrate. Data 
expressed as percent LTD4 converted (left y-axis) 
and picomoles LTD4 converted (right y- axis). 
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Fig. 17 . Relationship between3H-LTD4 conversion and 
substrate concentration expressed as picomoles/ml. 
Experimental procedure as described in Fig. 16, 
except that different substrate concentrations of 
varying specific radioactivity were used. Data 
expressed as picomoles converted/ml/min. 
Incubation period was 15 minutes. 
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Fig. 18.Relationship between LTD4 conversion and amount of 
serum present. 100 ul of 2-fold serial dilutions 
for human and mouse serum we're used. Experimental 
procedure as described in Fig. 16. Incubation 
period was 15 minutes. Data expressed as percent 
LTD4 converted (left y axis) and picomoles LTD4 
converted (right y axis). 
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Fig. 19.Dipeptidase activity in heat treated and untreated 
human and mouse serum after 30 minutes incubation. 
The dipeptidase activity was assayed as per 
procedure described in Fig 16. 
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Fig. 20.Effect of increasing amounts of heated human serum 
on the dipeptidase activity in normal human serum 
after 30 minutes incubation. Data expressed as 
percent conversion (left y axis), as well as 
picomoles of LTD4 converted (right y axis) . 
Different amounts of heat inactivated serum were 
added to 100 ul of 1/8 dilution of normal human 
serum brought to 250 ul with Hartmann's solution 
and 0.1% Triton X-100 and incubated with 160 
picomoles3H-LTD4 (22,000 dpms). 
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Fig. 21.Comparison of dipeptidase activity in normal human 
and mouse serum in presence of heat inactivated 
human or mouse serum after 30 minutes incubation. 
Procedure as described in Fig 20. Data expressed 
as percent LTD4 converted (left y-axis) and 
picomoles LTD„ converted (right y-axis) . 
Leukotriene Metabolism in different animal species 
The metabolism of 3H-LTC4 and 3H-LTD4 in human, mouse, 
guinea pig and rabbit sera were compared by time course 
studies. No studies were done to compare the conversion of 
LTC4 and LTD4 with relation to the volume of serum present, 
or substrate concentration. Fig. 22 and Fig. 23 show the 
difference in the profile of 3H-LTC4 and 3H-LTD4 metabolism in 
the four species. Fig. 24 shows the relative amount of 3H-
LTD4 present in the converted 3H-LTC4 in the four species 
after specific incubation times. Fig.25 shows the amount 
of LTD4 present as a percent of the total 3H-LTC4 
metabolized. The wide variation of this value in the four 
species and the correlation of this value with the 
susceptibility to develop anaphylaxis made it necessary to 
repeat the experiment. In the following experiment, in 
which fresh serum was used, horse and cow serum and fetal 
bovine serum (FBS) were included. Fig 26 and Fig. 27 show 
the time course of LTC4 and LTD4 conversion in the different 
species. Fig.28 shows the relative amount of3H-LTD4 
present, as a percentage of the total converted 3H-LTC4, 
after 15, 60 and 90 min incubation. Fig. 29 shows a 
comparison of the relative amounts of a radioactive 
metabolite of 3H-LTD4 metabolism, which has not been 
identified. The values mentioned in this experiment are an 
average of the results from experiments done in duplicate 
(Table II). 
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Fig. 22.Comparison of transpeptidase activity in human, 
mouse, guinea pig and rabbit serum. Procedure as 
described in Fig 15. Data expressed as percent LTC, 
converted (left y-axis) and picomoles LTC4 
converted (right y-axis). 
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Fig. 23.Comparison of dipeptidase activity in human, mouse, 
guinea pig and rabbit serum. Procedure as described 
in Fig 16. Data expressed as percent LTD4 converted 
(left y-axis) and as picomoles LTD4 converted 
(right y-axis). 
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Fig. 24.Comparison of3H-LTC4 conversion in human, mouse, 
guinea pig and rabbit serum. The amount of LTC4 
converted is expressed as relative amount of LTD4 
and LTE4 present after 20 min and 90 min. incubation 
(percent conversion on left y-axis, picomoles 
converted on right y- axis) . 
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Fig. 25.Comparison of LTD4 present in the converted 3H-LTC4 
as a percentage of total converted LTC4 after 90 
minutes incubation. 
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Fig. 26.3H-LTC4 conversion in 100 ul of horse, cow, fetal 
bovine, human, rabbit, mouse, and guinea pig as a 
time course study. Procedure as described in Fig 
15. Data expressed as per cent LTC4 converted 
(left y axis) and picomoles LTC4 converted (right 
y axis) . 
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Fig. 27.Conversion of3H-LTD4 in 100 ul of horse, cow, 
fetal bovine, human, rabbit, mouse, and guinea 
pig as a time course study. Procedure as 
described in Fig 16. Data expressed as per cent 
LTD4 converted (left y axis) and picomoles LTD4 
converted (right y axis). 
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Fig. 28.Relative amounts of3H-LTD4 present in 100 ul of 
horse, cow, human, rabbit, mouse, and guinea pig 
sera after 15, 60 and 90 minutes. Data expressed 
as per cent of LTD4 present in the total converted 
3H-LTC4. 
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Fig. 29.Relative amount of the unknown radioactive 
substance present in the total converted LTD„ 
after 45 minutes incubation. 
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Time 
Points 
15 
30 
60 
90 
% LTC4 Conversion 
Animal 
Guinea 
Human Mouse Pig Rabbit Horse Cow 
9.06 0 
1.22 2.12 
9.05 0 
17.10 0 
34.43 6.68 
34.85 5.28 
57.23 5.98 
59.34 
1.60 0 
0 0 
1.63 1.61 
3.44 3.71 
3.96 7.44 
1.82 13.15 
3.35 17.10 
3.25 15.70 
88.90 78.19 
96.92 
98.50 76.74 
100 71.61 
99.05 96.85 
96.60 93.10 
98.04 95.75 
97.39 100 
% LTD4 Conversion 
Animal 
Time Guinea 
Points Human Mouse Pig Rabbit Horse Cov 
5 2 .13 14. 63 4 .90 54 .67 39.79 18.47 
1.13 24.23 7.10 55.70 37.92 22.83 
15 11.11 63.46 7.10 88.07 67.85 42.47 
14.71 63.09 11.59 88.50 75.10 44.38 
30 43.45 73.69 8.82 90.00 87.13 68.36 
40.00 79.63 14.84 85.00 87.70 67.28 
45 52.66 81.36 16.53 97.21 92.70 75.16 
46.96 83.08 20.25 95.71 96.40 87.42 
"able II. Duplicate values obtained for percent conversion 
of 3H-LTC4 and 3H-LTD4 after varying periods of 
incubation in the sera of the different species 
tested. 
DISCUSSION: 
Arachidonic acid metabolites have been associated 
with a variety of inflammatory reactions. Products of the 
lipoxygenase pathway of metabolism, the peptidoleukotrienes 
(formerly referred to as SRS-A) are important mediators in 
immediate hypersensitivity reactions (24,54). Elevated 
levels of peptidoleukotrienes were noticed in bronchial 
asthma and are thought to be responsible for the symptoms in 
bronchial asthma, which is an immediate hypersensitivity 
reaction. Elevated leukotriene release from lungs of 
animals, during experimentally induced anaphylactic 
reactions have been reported (18,30,53,62). The profile of 
leukotriene metabolism in different species of animals were 
studied to see if a correlation exists between the 
leukotriene metabolism profile, and the relative species 
susceptibility to develop anaphylaxis. 
Using 3H-LTC4 as substrate, supernatant from RBL-1 
cells were seen to convert LTC4 to other radioactive 
substances, which eluted, during RP-HPLC, at times 
corresponding to synthetic LTD4 and LTE4. The conversion of 
3H-LTC4, was enzymatic since it was not seen to take place 
in a buffer (Fig. 5). 
Lipid extraction and analytical procedures, that gave 
satisfactory results with RBL-1 cells, were employed to 
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extract the leukotrienes from human serum. 3H-LTC4 was 
metabolized by human serum, with the production of new 
radioactive products, which eluted with synthetic LTD4 and 
LTE4. Conversion of 3H-LTC4 or 3H-LTD4 was not observed in 
Hartmann's solution at 37°C, serum at 4°C, or in protein 
denatured serum(Fig. 6,7). The metabolism of 3H-LTC4 in 
human serum was dependent on time, amount of enzyme present 
(volume of serum) and on the substrate concentration (Fig. 
11, 12, 13). In the time course study (Fig. 8), more 
radioactivity was seen in the LTD4 region with shorter 
incubation periods. As incubation time increased, the 
amount of radioactivity decreased in the LTD4 region and 
increased in the LTE4 region, showing that LTC4 was first 
converted to LTD4, which was then converted to LTE4. These 
findings are in accordance with the current knowledge about 
LTC4 metabolism; that LTC4 is first converted to LTD4 and 
that LTD4 is then converted to LTE4 (24, 54) . 
The enzymatic activity in serum was influenced by 
storage conditions. Prolonged storage at temperatures above 
-70°C were seen to decrease the conversion of LTD4 to LTE4 
(Fig.10) . A difference in LTD4 conversion was also noticed 
using heparinized versus clotted blood. When blood was 
heparinized, the LTD4 conversion was the same as in clotted 
blood, when assayed immediately; however, when heparinized 
blood was stored overnight at 4°C, prior to separation of 
plasma, the amount of LTD4 converted was seen to be reduced 
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(Fig. 9) . The LTD4 conversion requires Ca2+, Mg2+, and Mn2+ 
for optimal activity (39,52). The presence of substances 
like L-cysteine and dithiothreotol, which remove divalent 
cations from the medium are known to inhibit the LTD4 
conversion (39). Subsequent addition of these cations at 1 
mM concentration was seen to restore the lost activity (39). 
Although the anticoagulant effect of heparin is not due to 
the removal of Ca2+, it is possible that it is acting as an 
inhibitor of LTD4 conversion because it has the property of 
activating protease inhibitors, which in turn prevent the 
conversion of prothrombin to thrombin (70). 
Initially, leukotriene metabolism in serum of normal 
Balb-C mouse was compared with that in human serum. The 
profile in normal mouse serum was seen to be very different 
from that in humans (Fig.14,15). After 30 minutes 
incubation, 0.5 ml of normal human serum showed 67% 
conversions, with 34.6% recovered as LTD4 and 15.1% as 
LTE4. The mouse serum showed only 13.4% conversion, and 
all the radioactivity of the metabolized 3H-LTC4 was 
recovered as LTE4. It was presumed from these results, that 
the formation of LTD4 must be a much slower process in mouse 
than in humans, and that the LTD4 formed was immediately 
converted to LTE4. Subsequent experiments with 3H-LTD4 as 
substrate, showed that the amount of LTE4 formed during LTD4 
conversion was 4.2 times more in mouse than in humans 
(Fig.16). These findings correlate with results of 
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experiments by Applegreen and Hammarstrom (4), who found 
that 20 minutes after intravenous injection of 3H-LTC3 into 
mice, the radioactivity was recovered as LTC3 in liver and 
other organs. 3H-LTE3 was detected only in the lung, after 
60 minutes. Recovery of 3H-LTD3 was not reported in any 
tissue. LTC3 has been reported as having similar biological 
activity and enzyme specificity as LTC4 (21); therefore the 
profile of LTC3 metabolism should reflect that of LTD4. 
Since LTD4 is biologically the most potent 
peptidoleukotriene, the absence of LTD4 accumulation in 
mouse serum, correlates with the reported resistance to the 
development of anaphylaxis in the mouse (35,45,69). 
The conversion of LTD4 was studied in mouse and human 
sera, in the same way as the LTC4 conversion, using 3H-LTD4 
as substrate. The rate of conversion of LTD4 increased with 
time, as well as with substrate concentration (Fig.16 and 
17). However, the rate of reaction did not decrease in a 
linear manner, with increasing dilutions (Fig. 18). The 
rate of conversion increased up to a dilution of 1/8, and 
then declined. This observation implied that the serum 
contained another factor, the presence of which was reducing 
LTD4 conversion, in the undiluted form. Initial dilutions 
could have diluted the effect of this factor, leading to an 
increase in the LTD4 conversion. 
The presence of an inhibitor of LTD4 conversion has 
been mentioned briefly, by Raulf and coworkers in 1985 
(51). They suggested that a rapid decline in LTD4 
conversion in supernatant of stimulated RBL-1 cells was 
probably due to the presence of inhibitors. An attempt was 
made to study the nature of this "inhibitor" in serum. The 
enzyme activity in the serum was destroyed by immersing 
serum in a 65°C water bath for 30 minutes (Fig. 19) . This 
temperature was chosen, because temperatures above 65°C 
solidify the serum, due to coagulation of serum proteins, 
making it unfit for enzyme assay. Addition of heat 
inactivated human serum to unheated human serum was seen to 
decrease the LTD4 conversion by the unheated serum, in a 
concentration dependent manner (Fig.20). The effect of heat 
inactivated human and mouse serum, on unheated human and 
mouse serum, was compared. The heat inactivated human 
serum, seemed to contain larger amounts of the "inhibitory 
substance'', as shown by the dramatic reduction of activity 
in normal mouse serum (which showed high rate of LTD4 
conversion), as compared to the reduction of activity in 
human serum. Heat inactivated mouse serum did not have as 
much an inhibitory effect on mouse serum, or on human serum 
(Fig.21). Based on the results of this experiment, human 
serum was thought to contain a higher concentration of an 
unknown heat stable substance, which decreased the rate of 
conversion of LTD4. This "inhibitory factor", could have 
increased the accumulation of 3H-LTD4 in human serum. 
Absence, or a less amount of this substance in mouse serum 
might contribute to the higher resistance offered by mice to 
the development of anaphylaxis. Further studies, leading 
to characterization of this "inhibitory factor" are now in 
progress. 
The interesting results obtained by comparing human and 
mouse serum, with respect to leukotriene metabolism, and the 
correlation of these results with the anaphylactic reaction 
in these two species, lead us to conduct similar experiments 
on sera of other animal species. Guinea pigs and rabbits 
are reported to develop severe anaphylactic reactions (9). 
Anaphylactic reactions in horse and cattle have also been 
described (8). In an effort to identify a basis for the 
differences in hypersensitivity reactions, 3H-LTC4 and 3H-
LTD4 were used as substrates to study the profile of 
leukotriene metabolism in human, mouse, guinea pig and 
rabbit serum. The profile of LTC4 conversion different in 
all four species (Fig. 22). It was highest in human serum, 
32% being converted by 100 ul of serum after 60 min 
incubation. Rabbit and mouse sera showed a similar profile, 
6% and 4% being converted after 60 min, while guinea pig 
serum showed least activity, 0% LTC4 being converted after 
60 min. LTD4 is the most potent of the peptidoleukotrienes, 
with respect to biological activity. Therefore the relative 
amount of LTD4 present as a percent of the total converted 
3H-LTC4 was determined (Fig. 24 and 25). Larger amounts 
were present in human, guinea pig and rabbit sera, 25, 65 
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and 72% being present respectively. In the mouse serum, 
only 4% of the converted 3H-LTC4 was present as 3H-LTD4. The 
difference in the relative amount of LTD4 present suggested 
a difference in the metabolism of LTD4. Using 3H-LTD4 as a 
substrate, LTD4 metabolism in the four species was compared 
(Fig.23). The mouse serum showed highest activity, which 
accounted for the negligible amounts of LTD4 accumulation in 
mouse serum. The susceptibility to the development of 
anaphylaxis, in the different species described by earlier 
workers (9,50), seemed to be related to the rates of 
synthesis and metabolism of LTD4; i.e., the lower the rate 
of LTD4 synthesis, or the higher the rate of LTD4 
conversion, less prone was the animal to develop a severe 
anaphylactic reaction. 
The above experiment was done using sera stored at 
-70°C immediately after collection. Another experiment was 
designed using fresh serum from each species. In this 
experiment, which was done in duplicate, the serum was 
placed at 4°C (for 1 hour maximum time) until the assay was 
done. Sera from horse, cow and fetal bovine were also 
included. The mouse serum in this experiment came from 
Swiss Webster (SW) mice, whereas in the previous experiment 
it was collected from Balb-C mice. Sera from horse, cow and 
FBS showed maximal activity, more than 50% of LTC4 being 
converted in the first 15 min of incubation (Fig.26). 
Metabolism in human, rabbit, guinea pig and mouse sera 
showed similar patterns as those described above. However, 
there were differences in the relative amounts of LTD4 
produced. The relative amounts of LTD4 present after 15, 60 
and 90 min. incubation are shown in Fig. 28. In mouse 
serum, 100% of the converted LTC4 after a 60 min incubation 
was seen as LTD4, in contrast to the complete conversion to 
LTE4 in the previous experiment. Nevertheless, only 6.7% of 
the 3H-LTC4 was metabolized. Moreover, a high rate of LTD4 
conversion was observed in the mouse serum, which could 
could lower the LTD4 level as soon as it arises. A 
significant decrease in the LTD4 levels was seen after 90 
min. This difference seen between the two experiments, may 
be due to a strain difference. Since development of 
anaphylaxis is thought to be genetically controlled (58), it 
could be that a strain to strain difference exists in the 
susceptibility to develop anaphylaxis. A strain difference 
in asthma models in rats has been reported (37). Experiments 
dealing with induction of anaphylaxis in different strains 
of mice are necessary to confirm this view. 
The addition of 3H-LTC4 to rabbit serum resulted in 
the accumulation of a large amount of 3H-LTD4 even after 90 
minutes incubation (Fig. 28). This correlated with the 
susceptibility of the animal to develop anaphylaxis. In the 
presence of a high rate of LTC4 conversion, a slower rate of 
LTD4 conversion would be expected, in order to maintain high 
levels of LTD4 even after 90 minutes incubation with 3H-LTC4. 
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Surprisingly, rabbit serum showed a high rate of 3H-LTD4 
conversion (Fig.27). This observation was different from 
that in the previous experiment. In human serum, a large 
amount of LTD4 was present after 60 and 90 min incubation 
(Fig.28). This appeared to result from a high rate of LTC4 
metabolism and a lower rate of conversion of LTD4 to LTE4. 
This metabolic profile might maintain a high level of LTD4 
for prolonged periods of time. This pattern of leukotriene 
metabolism might, therefore contribute to the prolonged 
symptoms of anaphylaxis in humans, ( eg., the symptoms of 
bronchial asthma). The slow rate of metabolism of LTD4 
might account for the high amounts of LTD4 in the 
supernatant from alveolar macrophages in asthmatics 
individuals, as compared to those from normal individuals, 
reported by Damon and coworkers (17).. However, 
Schwartzberg and coworkers (56), and Isono and coworkers 
(26) found only LTC4 in the serum during an acute asthmatic 
attack in children. These findings suggest that during an 
acute asthmatic attack, the metabolism of leukotrienes in 
the lung might be different from that in the blood. 
The LTC4 conversion as well as the LTD4 conversion 
activity in guinea pig serum seemed to be the lowest of all 
sera tested (Fig. 26,27). Although the rate of conversion 
of LTC4 was low, the slow rate of LTD4 conversion might be 
responsible for accumulation of the converted 3H-LTC4 as 
LTD4. These observations correlate with those of in vivo 
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experiments conducted by Keppler et al (30), where LTD4 was 
the main metabolite in bile following anaphylactic shock in 
the guinea pig. Clancy and coworkers (15) have reported 
LTD4 as the main metabolite in the supernatant of guinea pig 
lung tissue after incubation with LTC4. De Nucci and 
coworkers (18) have identified LTD4 as the main metabolite 
in perfused lung tissue, after antigen challenge. Guinea 
pig and mouse sera showed a similarity in the profile of 3H-
LTC4 metabolism. On comparing the relative amounts of LTD4 
following 3H-LTC4 metabolism, 100% of the metabolized 3H-LTC4 
was recovered as LTD4 after 60 minutes incubation. However, 
the rapid rate of LTD4 conversion in mouse serum brought 
about a reduction in the 3H-LTD4 levels after 90 minutes 
incubation (Fig 28) . This suggests that LTD4 conversion is 
more important than LTC4 conversion in controlling -the 
accumulation of LTD4. 
Although guinea pig and rabbit sera are similar in the 
relative amounts of LTD4 present, the anaphylactic reaction 
is different in the two species. In guinea pig, the 
anaphylactic reactions mimic that in humans, and the 
respiratory distress is similar to that seen in bronchial 
asthma in humans (50). These symptoms are due to narrowing 
of bronchioles due to smooth muscle constriction. Although 
respiratory distress occurs in rabbit, it is not due to 
bronchoconstriction, but rather due to constriction of the 
pulmonary artery. This has been shown by experiments in 
which a rise in pulmonary arterial pressure was demonstrated 
(16). The pulmonary artery of the rabbit has a more 
developed smooth muscle layer, whereas the bronchioles have 
less smooth muscle than in the guinea pig. After fatal 
anaphylaxis, a difference in lung pathology supports the 
fact that in rabbit, death is due to cardiac failure due to 
raised pulmonary arterial pressure, whereas in guinea pig it 
is due to bronchoconstriction (50). For these reasons, the 
guinea pig is known to be a better experimental animal model 
for bronchial asthma. 
In horse and cow serum, both LTC4 and LTD4 conversion 
were seen to be high, reaching almost maximal levels after 
15 min incubation (Fig.26,27). Although large amounts of 
3H-LTD4 are formed in the initial stages, these levels 
decline rapidly due to increased LTD4 conversion. This 
observation correlates with the description of the 
anaphylactic reaction in horse and cattle (8), where the 
symptoms of respiratory distress develop within 8-15 
minutes, and then subside spontaneously. The horse and cow 
serum appeared to be similar to human serum in that 
significant amounts of LTD4 were present after 15 min 
incubation. This might be one of the factors responsible 
for the similarity in symptoms of anaphylaxis between 
humans, horse and cattle (50). 
The relative amounts of LTD4 present were expressed 
as a percentage of the total converted 3H-LTC4. The 
radioactive substances other than LTD4 were not always 
confined to the LTE4 region. In certain species, as in 
horse, and in FBS, an additional radioactive peak was seen 
immediately after the elution of LTE4. The elution time of 
this metabolite did not coincide with that of standard 
preparations of LTC4, LTD4, LTE4, N-acetyl LTE4, or LTF4. The 
formation of this unknown substance did not appear to be 
related to the rate of LTD4 conversion reaction (Fig 29) , as 
it was not seen in rabbit and mouse serum which showed high 
rate of conversion of LTD4. Hammarstrom (23) has reported 
the presence of eight LTC4 metabolites in the feces of rats 
after subcutaneous injection of 3H-LTC4. Several of these 
have not yet been identified. Until this substance has been 
identified, and its biological activity assessed, it cannot 
be concluded if the formation of this substance enhances or 
decreases the symptoms in an anaphylactic reaction. 
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